PDCD1 and neoplasm: Despite diverse treatment methods, such as various types of PD-1 inhibitors, and varying cycles of nIT, and a few patients received nCT or nCRT before nIT, all patients received single-agent anti-PD-1 antibody as nIT strategy, and achieved ideal tumor regression with low irAEs and srAEs.